Christopher P Cannon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9381891/publications.pdf Version: 2024-02-01

		906	365
499	84,104	116	282
papers	citations	h-index	g-index
531	531	531	44494
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2009, 361, 1045-1057.	27.0	6,019
2	Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. New England Journal of Medicine, 2004, 350, 1495-1504.	27.0	4,527
3	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2019, 380, 2295-2306.	27.0	3,760
4	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine, 2015, 372, 2387-2397.	27.0	3,337
5	Third Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, 1581-1598.	2.8	2,558
6	Third universal definition of myocardial infarction. European Heart Journal, 2012, 33, 2551-2567.	2.2	2,447
7	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine, 2013, 369, 1327-1335.	27.0	2,261
8	C-Reactive Protein Levels and Outcomes after Statin Therapy. New England Journal of Medicine, 2005, 352, 20-28.	27.0	2,103
9	Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban. New England Journal of Medicine, 2001, 344, 1879-1887.	27.0	1,918
10	Predictors of Hospital Mortality in the Global Registry of Acute Coronary Events. Archives of Internal Medicine, 2003, 163, 2345.	3.8	1,856
11	Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. New England Journal of Medicine, 2005, 352, 1179-1189.	27.0	1,739
12	Cardiac-Specific Troponin I Levels to Predict the Risk of Mortality in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 1996, 335, 1342-1349.	27.0	1,589
13	The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2001, 345, 1014-1021.	27.0	1,217
14	Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2011, 305, 1097.	7.4	1,185
15	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. New England Journal of Medicine, 2017, 377, 1513-1524.	27.0	1,099
16	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 2021, 384, 117-128.	27.0	1,080
17	Relationship of Symptom-Onset-to-Balloon Time and Door-to-Balloon Time With Mortality in Patients Undergoing Angioplasty for Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2000, 283, 2941.	7.4	1,047
18	Clopidogrel with or without Omeprazole in Coronary Artery Disease. New England Journal of Medicine, 2010, 363, 1909-1917.	27.0	1,019

#	Article	IF	CITATIONS
19	Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. New England Journal of Medicine, 2020, 383, 1425-1435.	27.0	927
20	Acute myocardial infarction. Lancet, The, 2017, 389, 197-210.	13.7	869
21	Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). European Heart Journal, 2003, 24, 1815-1823.	2.2	800
22	Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. New England Journal of Medicine, 2017, 377, 1217-1227.	27.0	780
23	C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy. Journal of the American College of Cardiology, 1998, 31, 1460-1465.	2.8	718
24	Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. New England Journal of Medicine, 2010, 363, 2406-2415.	27.0	697
25	Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease. Circulation, 2007, 115, 2761-2788.	1.6	694
26	Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction. Circulation, 2012, 126, 65-75.	1.6	681
27	Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes. Circulation, 2002, 105, 1760-1763.	1.6	680
28	Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy. Journal of the American College of Cardiology, 2006, 48, 438-445.	2.8	668
29	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2021, 384, 129-139.	27.0	662
30	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet, The, 2015, 385, 2067-2076.	13.7	659
31	Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. JAMA Cardiology, 2021, 6, 148.	6.1	625
32	Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet, The, 2010, 375, 283-293.	13.7	624
33	Diabetes and Mortality Following Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2007, 298, 765.	7.4	569
34	Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet, The, 2015, 385, 2264-2271.	13.7	564
35	Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet, The, 2010, 375, 1536-1544.	13.7	544
36	Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial. Journal of the American College of Cardiology, 2008, 51, 724-730.	2.8	534

#	Article	IF	CITATIONS
37	Utilization of Early Invasive Management Strategies for High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2004, 292, 2096.	7.4	525
38	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet, The, 2019, 393, 407-415.	13.7	512
39	Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack. Circulation, 2009, 119, 107-115.	1.6	505
40	Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention. Circulation, 2010, 122, 2131-2141.	1.6	474
41	Hospital Delays in Reperfusion for ST-Elevation Myocardial Infarction. Circulation, 2006, 114, 2019-2025.	1.6	472
42	Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2007, 50, 1844-1851.	2.8	471
43	Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. New England Journal of Medicine, 2014, 370, 1702-1711.	27.0	467
44	Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet, The, 2006, 368, 1771-1781.	13.7	458
45	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. Journal of the American College of Cardiology, 2011, 57, 672-684.	2.8	457
46	Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction. Circulation, 2001, 103, 2550-2554.	1.6	440
47	Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2007, 50, 1852-1856.	2.8	438
48	Association Between Influenza Vaccination and Cardiovascular Outcomes in High-Risk Patients. JAMA - Journal of the American Medical Association, 2013, 310, 1711.	7.4	399
49	Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation, 2011, 124, 544-554.	1.6	397
50	Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. Journal of Clinical Lipidology, 2015, 9, 758-769.	1.5	390
51	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. Clinical Chemistry, 2007, 53, 552-574.	3.2	383
52	Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2014, 312, 1006.	7.4	375
53	Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal, 2009, 157, 599-605.	2.7	363
54	Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function. Circulation, 2010, 122, 1056-1067.	1.6	354

#	Article	IF	CITATIONS
55	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes. Circulation, 2007, 115, e356-75.	1.6	348
56	Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. European Heart Journal, 2015, 36, 1186-1194.	2.2	344
57	Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2010, 56, 1456-1462.	2.8	339
58	Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clinic Proceedings, 2009, 84, 917-938.	3.0	310
59	Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin Therapy. Journal of the American College of Cardiology, 2005, 46, 1411-1416.	2.8	306
60	Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus. Circulation, 2018, 137, 1571-1582.	1.6	304
61	Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. American Heart Journal, 2015, 169, 906-915.e13.	2.7	294
62	Complementary Roles for Biomarkers of Biomechanical Strain ST2 and N-Terminal Prohormone B-Type Natriuretic Peptide in Patients With ST-Elevation Myocardial Infarction. Circulation, 2008, 117, 1936-1944.	1.6	290
63	Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial. Circulation, 2000, 102, 149-156.	1.6	281
64	Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International) Tj ETQq outcomes in patients with acute coronary syndromes. American Heart Journal, 2008, 156, 826-832.	0 0 0 rgBT / 2.7	Overlock 10 280
65	Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT. Circulation, 2015, 132, 1224-1233.	1.6	267
66	The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects of Statins in the Management of Acute Coronary Syndromes. Journal of the American College of Cardiology, 2005, 46, 1425-1433.	2.8	248
67	Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ: British Medical Journal, 2011, 342, d3527-d3527.	2.3	246
68	Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. European Heart Journal, 2014, 35, 2864-2872.	2.2	238
69	Use of Aldosterone Antagonists in Heart Failure. JAMA - Journal of the American Medical Association, 2009, 302, 1658.	7.4	231
70	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation, 2018, 138, 527-536.	1.6	211
71	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation, 2019, 140, 739-750.	1.6	211
72	Lipoprotein-Associated Phospholipase A ₂ and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or) Tj ETQq0 0 0 1	rgBT_/Overl	ock 10 Tf 50

Circulation, 2006, 113, 1745-1752.

#	Article	IF	CITATIONS
73	What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes?. Circulation, 2010, 122, 2142-2151.	1.6	207
74	Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation, 2019, 139, 1384-1395.	1.6	205
75	In-Hospital Major Bleeding During ST-Elevation and Non–ST-Elevation Myocardial Infarction Care: Derivation and Validation of a Model from the ACTION Registry®-GWTG™. American Journal of Cardiology, 2011, 107, 1136-1143.	1.6	202
76	Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 680-688.	2.2	198
77	Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. JAMA Cardiology, 2019, 4, 747.	6.1	198
78	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. American Journal of Nephrology, 2017, 46, 462-472.	3.1	194
79	A Call to ACTION (Acute Coronary Treatment and Intervention Outcomes Network). Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 491-499.	2.2	187
80	Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. Journal of the American College of Cardiology, 2017, 70, 1689-1700.	2.8	186
81	Acute Clopidogrel Use and Outcomes in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. Journal of the American College of Cardiology, 2006, 48, 281-286.	2.8	179
82	Inflammatory Biomarkers Interleukinâ€6 and Câ€Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of) Tj ETQq0 0 0 rg	BT3Øverla	ock1 29 Tf 50 3
83	Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor. Circulation, 2012, 125, 978-986.	1.6	176
84	Reduction in Total Cardiovascular Events WithÂEzetimibe/Simvastatin Post-Acute Coronary Syndrome. Journal of the American College of Cardiology, 2016, 67, 353-361.	2.8	173
85	Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal, 2014, 35, 2083-2093.	2.2	171
86	Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). American Heart Journal, 2018, 206, 11-23.	2.7	171
87	Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. European Heart Journal, 2011, 32, 2945-2953.	2.2	169
88	Prognostic Utility of Heart-Type Fatty Acid Binding Protein in Patients With Acute Coronary Syndromes. Circulation, 2006, 114, 550-557.	1.6	168
89	Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. European Heart Journal, 2008, 29, 1096-1102.	2.2	168
90	Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. European Heart Journal, 2013, 34, 1204-1214.	2.2	167

#	Article	IF	CITATIONS
91	Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet, The, 2020, 396, 1637-1643.	13.7	167
92	Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention. Circulation, 2011, 123, 1622-1632.	1.6	166
93	The Evolving Future of PCSK9 Inhibitors. Journal of the American College of Cardiology, 2018, 72, 314-329.	2.8	162
94	Sodiumâ€Clucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2020, 9, e014908.	3.7	161
95	Reduction in Recurrent Cardiovascular Events With Intensive Lipid-Lowering Statin Therapy Compared With Moderate Lipid-Lowering Statin Therapy After Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 54, 2358-2362.	2.8	159
96	Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. European Heart Journal, 2009, 30, 1195-1202.	2.2	157
97	Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. Journal of the American College of Cardiology, 2017, 69, 911-921.	2.8	157
98	Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease. Circulation, 2020, 142, 2205-2215.	1.6	156
99	Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease. Journal of the American College of Cardiology, 2014, 63, 520-527.	2.8	152
100	Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: The Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry®–Get With The Guidelines (GWTG)â,,¢ acute myocardial infarction mortality model and risk score. American Heart Journal. 2011. 161. 113-122.e2.	2.7	149
101	Antithrombotic Therapy for Non–ST-Segment Elevation Acute Coronary Syndromes. Chest, 2008, 133, 670S-707S.	0.8	145
102	Cardiovascular Risk and Statin Eligibility ofÂYoung Adults After an MI. Journal of the American College of Cardiology, 2018, 71, 292-302.	2.8	145
103	Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol. JAMA Cardiology, 2017, 2, 547.	6.1	144
104	2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology, 2021, 77, 629-658.	2.8	144
105	Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 203-210.	2.4	138
106	EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE). American Heart Journal, 2011, 162, 620-626.e1.	2.7	138
107	Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets, 2014, 25, 517-525.	2.3	138
108	Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 424-430.	2.4	136

#	Article	IF	CITATIONS
109	Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. European Heart Journal, 2018, 39, 1726-1735a.	2.2	133
110	Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: Are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. American Heart Journal, 2003, 145, 622-627.	2.7	132
111	Onset and Offset of Platelet Inhibition After High-Dose Clopidogrel Loading and Standard Daily Therapy Measured by a Point-of-Care Assay in Healthy Volunteers. American Journal of Cardiology, 2006, 98, 681-684.	1.6	130
112	Age and Gender Differences in Quality of Care and Outcomes for Patients with ST-segment Elevation Myocardial Infarction. American Journal of Medicine, 2012, 125, 1000-1009.	1.5	128
113	Management of Antithrombotic Therapy in Atrial Fibrillation Patients UndergoingÂPCI. Journal of the American College of Cardiology, 2019, 74, 83-99.	2.8	126
114	Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA Cardiology, 2017, 2, 959.	6.1	124
115	Cost and Cost-effectiveness of an Early Invasive vs Conservative Strategy for the Treatment of Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2002, 288, 1851.	7.4	122
116	Cardiovascular disease and modifiable cardiometabolic risk factors. Clinical Cornerstone, 2007, 8, 11-28.	0.7	122
117	Adherence to Secondary Prevention Medications and Four-year Outcomes in Outpatients with Atherosclerosis. American Journal of Medicine, 2013, 126, 693-700.e1.	1.5	121
118	The Relative Efficacy and Safety of Clopidogrel in Women and Men. Journal of the American College of Cardiology, 2009, 54, 1935-1945.	2.8	119
119	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation, 2021, 143, 583-596.	1.6	119
120	Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)—TIMI 22 trial. American Journal of Cardiology, 2002, 89, 860-861.	1.6	118
121	Circadian Variation in the Onset of Unstable Angina and Non-Q-Wave Acute Myocardial Infarction (The) Tj ETQq1	1,0,7843 1.6	14 rgBT /Ove
122	The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and) Tj ETQq0 0 0 r	g B∄.≉ Overl	odata:0 Tf 50
123	COX-2 Inhibitors and Cardiovascular Risk. Science, 2012, 336, 1386-1387.	12.6	115
124	Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. European Heart Journal, 2018, 39, 2540-2545.	2.2	113
125	An Organized Approach to Improvement in Guideline Adherence for Acute Myocardial Infarction. Archives of Internal Medicine, 2008, 168, 1813.	3.8	112
126	Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of) Tj ETQq0 0 0 rgBT /O patients with coronary heart disease. American Heart Journal, 2010, 160, 655-661.e2.	verlock 10 2.7	Tf 50 67 Td 111

#	Article	IF	CITATIONS
127	Acute ST-Segment Elevation Myocardial Infarction. Chest, 2008, 133, 708S-775S.	0.8	110
128	Reductions in Atherogenic Lipids and Major Cardiovascular Events. Circulation, 2016, 134, 1931-1943.	1.6	110
129	Synthesizing Lessons Learned From Get With The Guidelines. Circulation, 2013, 128, 2447-2460.	1.6	106
130	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 1128-1139.	6.1	106
131	Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia, 2021, 64, 1256-1267.	6.3	103
132	Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International) Tj ETQq0 0	01gBT /O	ve iloz k 10 Tf
133	Prescriber Patterns ofÂSGLT2i After Expansions of U.S.ÂFoodÂand Drug Administration Labeling. Journal of the American College of Cardiology, 2018, 72, 3370-3372.	2.8	102
134	Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization. Circulation, 2014, 129, 293-303.	1.6	100
135	Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	3.7	100
136	Treatment of Hypertension in Patients With Coronary Artery Disease. Hypertension, 2015, 65, 1372-1407.	2.7	97
137	Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. Clinical Chemistry, 2017, 63, 325-333.	3.2	97
138	Interleukinâ€6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLIDâ€TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in) Tj ETQq0 0	03gBT /O	ve st ock 10 Tf
139	Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 934-943.	11.4	96
140	Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. Circulation, 2019, 140, 618-620.	1.6	96
141	Biomarker-Based Risk Model to PredictÂCardiovascular Mortality in PatientsÂWithÂStableÂCoronaryÂDisease. Journal of the American College of Cardiology, 2017, 70, 813-826.	2.8	95
142	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%. Circulation, 2020, 141, 407-410.	1.6	95
143	Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. American Heart Journal, 2014, 168, 205-212.e1.	2.7	93
144	PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. European Heart Journal, 2015, 36, 2415-2424.	2.2	93

#	Article	IF	CITATIONS
145	Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney International, 2021, 99, 999-1009.	5.2	93
146	Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication. Hypertension, 2016, 68, 1355-1364.	2.7	92
147	Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. European Heart Journal, 2006, 27, 2323-2329.	2.2	88
148	Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1705-1714.	4.5	87
149	Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. JAMA Cardiology, 2021, 6, 1060.	6.1	86
150	Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib. American Heart Journal, 2009, 158, 513-519.e3.	2.7	85
151	Association of Hospital Primary Angioplasty Volume in ST-Segment Elevation Myocardial Infarction With Quality and Outcomes. JAMA - Journal of the American Medical Association, 2009, 302, 2207.	7.4	83
152	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	83
153	Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney International, 2018, 93, 1397-1408.	5.2	83
154	An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. American Heart Journal, 2010, 159, 705-709.	2.7	82
155	Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older. JAMA Cardiology, 2019, 4, 846.	6.1	81
156	Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery. Journal of the American College of Cardiology, 2012, 60, 1623-1630.	2.8	80
157	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. European Heart Journal, 2021, 42, 4891-4901.	2.2	80
158	Mixed Dyslipidemia, Metabolic Syndrome, Diabetes Mellitus, and Cardiovascular Disease: Clinical Implications. American Journal of Cardiology, 2008, 102, 5L-9L.	1.6	78
159	Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease. American Journal of Cardiology, 2014, 113, 76-83.	1.6	78
160	Achieving rapid reperfusion with primary percutaneous coronary intervention remains a challenge: Insights from American Heart Association's Get With the Guidelines program. American Heart Journal, 2008, 155, 1059-1067.	2.7	77
161	Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. American Heart Journal, 2011, 162, 613-619.e1.	2.7	77
162	Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 633-641.	2.2	73

#	Article	IF	CITATIONS
163	Clinical Application of C-Reactive Protein Across the Spectrum of Acute Coronary Syndromes. Clinical Chemistry, 2007, 53, 1800-1807.	3.2	72
164	Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study. Circulation, 2013, 127, 673-680.	1.6	72
165	Predictors of Longâ€ŧerm Adherence to Evidenceâ€based Cardiovascular Disease Medications in Outpatients With Stable Atherothrombotic Disease: Findings From the <scp>REACH</scp> Registry. Clinical Cardiology, 2013, 36, 721-727.	1.8	72
166	The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. European Heart Journal, 2016, 37, 3576-3584.	2.2	71
167	Efficacy and Safety of Alirocumab 150Âmg Every 4ÂWeeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. Journal of the American Heart Association, 2016, 5, .	3.7	71
168	Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. JAMA Cardiology, 2020, 5, 582.	6.1	71
169	Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless ofÂAspirin Dose in Patients Requiring DualÂAntiplatelet Therapy. Journal of the American College of Cardiology, 2016, 67, 1661-1671.	2.8	69
170	Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. Journal of the American College of Cardiology, 2019, 73, 2439-2450.	2.8	69
171	Quality of Care for Acute Coronary Syndrome Patients With Known Atherosclerotic Disease. Circulation, 2009, 120, 560-567.	1.6	68
172	Effect of Medication Co-payment Vouchers on P2Y ₁₂ Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction. JAMA - Journal of the American Medical Association, 2019, 321, 44.	7.4	67
173	Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease. Circulation, 2016, 133, 1574-1581.	1.6	66
174	Design and Rationale of the <scp>REâ€ÐUAL PCI</scp> Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting, Clinical Cardiology, 2016, 39, 555-564	1.8	65
175	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2021, 325, 39.	7.4	65
176	Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy. Journal of the American College of Cardiology, 2008, 52, 914-920.	2.8	64
177	Door-to-Balloon Times in Hospitals Within the Get-With-The-Guidelines Registry After Initiation of the Door-to-Balloon (D2B) Alliance. American Journal of Cardiology, 2009, 103, 1051-1055.	1.6	63
178	Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. European Heart Journal, 2019, 40, 1553-1562.	2.2	62
179	Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. American Heart Journal, 2006, 152, 237-245.	2.7	61
180	Association of Influenza Vaccination With Cardiovascular Risk. JAMA Network Open, 2022, 5, e228873.	5.9	61

#	Article	IF	CITATIONS
181	Balancing the Benefit and Risk of Oral Antiplatelet Agents in Coronary Artery Bypass Surgery. Annals of Thoracic Surgery, 2005, 80, 768-779.	1.3	60
182	The Role of Clopidogrel in Early and Sustained Arterial Patency After Fibrinolysis for ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2006, 48, 37-42.	2.8	60
183	Pulmonary Function in Patients With Acute Coronary Syndrome Treated With Ticagrelor or Clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] Pulmonary Function) Tj ETQq1 1 0.7843	814 gBT ;	/Ov ed ock 10
184	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease. Circulation, 2021, 143, 1735-1749.	1.6	60
185	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease. Stroke, 2021, 52, 1545-1556.	2.0	60
186	Importance of TIMI 3 Flow. Circulation, 2001, 104, 624-626.	1.6	59
187	Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes. JAMA Cardiology, 2018, 3, 1160.	6.1	57
188	Current Use of Aspirin and Antithrombotic Agents in the United States Among Outpatients With Atherothrombotic Disease (from the REduction of Atherothrombosis for Continued Health [REACH]) Tj ETQq0 0	0 ng 8 T /C)ver tø ck 10 Tf
189	Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Atherosclerosis, 2019, 288, 194-202.	0.8	56
190	Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death. Clinical Chemistry, 2009, 55, 265-273.	3.2	54
191	Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin) Tj ETQq1 1 ().7 &\$ 314	rgB74/Overlo
192	Outcomes of Women Compared With Men After Non–ST-Segment Elevation AcuteÂCoronary Syndromes. Journal of the American College of Cardiology, 2019, 74, 3013-3022.	2.8	54
193	Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention, 2015, 11, 737-745.	3.2	54
194	Critical pathways for management of patients with acute coronary syndromes: An assessment by the National Heart Attack Alert Program. American Heart Journal, 2002, 143, 777-789.	2.7	53
195	Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: <scp>T</scp> he <scp>EXAMINE</scp> trial. Diabetes, Obesity and Metabolism, 2017, 19, 664-671.	4.4	53
196	Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. Journal of Lipid Research, 2013, 54, 467-472.	4.2	52
197	A Prospective Randomized Trial ofÂApixaban Dosing During AtrialÂFibrillationÂAblation. JACC: Clinical Electrophysiology, 2018, 4, 580-588.	3.2	52
198	Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. American Heart Journal, 2005, 149, 227-233.	2.7	51

#	Article	IF	CITATIONS
199	The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. International Journal of Cardiology, 2018, 270, 245-252.	1.7	51
200	Protection Conferred by Preinfarct Angina is Manifest in the Aged Heart: Evidence from the TIMI 4 Trial. Journal of Thrombosis and Thrombolysis, 1998, 6, 89-92.	2.1	48
201	Individualizing Blood Pressure Targets for People With Diabetes and Hypertension. JAMA - Journal of the American Medical Association, 2018, 319, 1319.	7.4	48
202	Predictors of Adherence to Performance Measures in Patients with Acute Myocardial Infarction. American Journal of Medicine, 2013, 126, 74.e1-74.e9.	1.5	47
203	Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial. Journal of the American College of Cardiology, 2014, 63, 1493-1499.	2.8	47
204	Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. Diabetes Care, 2016, 39, 1267-1273.	8.6	47
205	Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: Observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22). American Heart Journal, 2011. 161. 1147-1155.e1.	2.7	46
206	Temporal Trends and Predictors in the Use of Aldosterone Antagonists Post-Acute Myocardial Infarction. Journal of the American College of Cardiology, 2013, 61, 35-40.	2.8	46
207	Lipidâ€lowering efficacy and safety of alirocumab in patients with or without diabetes: <scp>A</scp> subâ€analysis of <scp>ODYSSEY COMBO II</scp> . Diabetes, Obesity and Metabolism, 2017, 19, 989-996.	4.4	46
208	Short Sleep Duration, Obstructive Sleep Apnea, Shiftwork, and the Risk of Adverse Cardiovascular Events in Patients After an Acute Coronary Syndrome. Journal of the American Heart Association, 2017, 6, .	3.7	46
209	Pointâ€ofâ€Care Platelet Function Testing Predicts Bleeding in Patients Exposed to Clopidogrel Undergoing Coronary Artery Bypass Grafting: Verify Preâ€Op <scp>TIMI</scp> 45—A Pilot Study. Clinical Cardiology, 2015, 38, 92-98.	1.8	45
210	Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. European Heart Journal, 2017, 38, 2813-2822.	2.2	45
211	Relationship of Race/Ethnicity With Doorâ€ŧoâ€Balloon Time and Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for <scp>ST</scp> â€Elevation Myocardial Infarction: Findings From Get With the Guidelines–Coronary Artery Disease. Clinical Cardiology, 2013, 36, 749-756.	1.8	44
212	Lipoproteinâ€Associated Phospholipase A ₂ Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. Journal of the American Heart Association, 2016, 5, .	3.7	44
213	NSAID Use and Association with Cardiovascular Outcomes in Outpatients with Stable Atherothrombotic Disease. American Journal of Medicine, 2014, 127, 53-60.e1.	1.5	43
214	Vitamin K antagonists with or without longâ€ŧerm antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events. Clinical Cardiology, 2017, 40, 932-939.	1.8	43
215	Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVEâ€IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Journal of the American Heart Association, 2017, 6, .	3.7	43
216	Heart failure with midâ€range ejection fraction: characterization of patients from the PINNACLE Registry®. ESC Heart Failure, 2019, 6, 784-792.	3.1	43

#	Article	IF	CITATIONS
217	Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. JAMA Cardiology, 2021, 6, 1440.	6.1	43
218	Guideline Adherence After ST-Segment Elevation Versus Non-ST Segment Elevation Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 654-661.	2.2	42
219	Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 543-549.	2.0	41
220	Breaking the therapeutic barriers: New Strategies for acute coronary syndromes. Clinical Cardiology, 1999, 22, 1-2.	1.8	40
221	Outcomes of Patients With Acute Coronary Syndrome and Previous Coronary Artery Bypass Grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the) Tj ETQq1 1 ().781.46314 r	gB4dOverloci
222	Comparison of Composite Measure Methodologies for Rewarding Quality of Care. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 610-618.	2.2	40
223	Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry. Diabetes, Obesity and Metabolism, 2019, 21, 1121-1127.	4.4	40
224	Digital Care Transformation. Circulation, 2021, 143, 507-509.	1.6	40
225	Very Large Database of Lipids: Rationale and Design. Clinical Cardiology, 2013, 36, 641-648.	1.8	39
226	Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. American Heart Journal, 2008, 155, 910-917.	2.7	38
227	Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart, 2014, 100, 1762-1769.	2.9	38
228	High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. American Heart Journal, 2018, 202, 97-103.	2.7	38
229	Prescription of Clucagon-Like Peptide-1 Receptor Agonists by Cardiologists. Journal of the American College of Cardiology, 2019, 73, 1596-1598.	2.8	38
230	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Journal of the American Heart Association, 2015, 4, e002490.	3.7	37
231	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 384-395.	4.5	37
232	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. American Heart Journal, 2017, 186, 91-99.	2.7	36
233	Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction. JAMA Cardiology, 2021, 6, 880.	6.1	36
234	Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). American Heart Journal, 2011, 161, 418-424.e3.	2.7	35

#	Article	IF	CITATIONS
235	Relationship Between Lowâ€Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipidâ€Lowering Strategies. Journal of the American Heart Association, 2016, 5, .	3.7	35
236	Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome. Journal of the American Heart Association, 2018, 7, e009077.	3.7	35
237	Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). American Heart Journal, 2010, 160, 1130-1136.e3.	2.7	33
238	Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome. JAMA Cardiology, 2018, 3, 473.	6.1	33
239	Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y ₁₂ Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial. Journal of the American Heart Association, 2019, 8, e011139.	3.7	33
240	Time to reperfusion: The critical modulator in thrombolysis and primary angioplasty. Journal of Thrombolysis, 1996, 3, 117-125.	2.1	32
241	Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. American Journal of Medicine, 2016, 129, 1002-1005.	1.5	32
242	Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. Journal of the American College of Cardiology, 2019, 74, 1057-1068.	2.8	32
243	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation, 2021, 143, 470-478.	1.6	32
244	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. Annals of Internal Medicine, 2021, 174, 1065-1072.	3.9	32
245	Can the polypill save the world from heart disease?. Lancet, The, 2009, 373, 1313-1314.	13.7	31
246	Temporal Trends for Secondary Prevention Measures Among Patients Hospitalized with Coronary Artery Disease. American Journal of Medicine, 2015, 128, 426.e1-426.e9.	1.5	31
247	The effect of canagliflozin on amputation risk in the <scp>CANVAS</scp> program and the <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2020, 22, 1753-1766.	4.4	31
248	Discharge Aspirin Dose and Clinical Outcomes in Patients With Acute Coronary Syndromes Treated With Prasugrel Versus Clopidogrel. Journal of the American College of Cardiology, 2014, 63, 225-232.	2.8	30
249	Economic Analysis of Ticagrelor Therapy From a U.S. Perspective. Journal of the American College of Cardiology, 2015, 65, 465-476.	2.8	30
250	Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. Journal of the American Society of Nephrology: JASN, 2017, 28, 3034-3043.	6.1	30
251	Highâ€sensitivity <scp>C</scp> â€reactive protein, lowâ€density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the <scp>EXAMINE</scp> (<scp>Examination of) Tj ETQq1 1 0.784 Metabolism. 2018. 20. 654-659.</scp>	1314 rgBT 4.4	/Oyerlock 10
252	Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial. Diabetes Care, 2018, 41, 1510-1515.	8.6	30

#	Article	IF	CITATIONS
253	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. American Heart Journal, 2021, 233, 141-148.	2.7	30
254	Care and Outcomes of Asian-American Acute Myocardial Infarction Patients: Findings From the American Heart Association Get With The Guidelines-Coronary Artery Disease Program. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 126-133.	2.2	28
255	Ezetimibe plus a Statin after Acute Coronary Syndromes. New England Journal of Medicine, 2015, 373, 1473-1477.	27.0	28
256	Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 398-405.	4.5	28
257	Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. European Heart Journal, 2018, 39, 3810-3820.	2.2	28
258	Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. Journal of the American Heart Association, 2020, 9, e012797.	3.7	28
259	Incorporating platelet glycoprotein iib/iiia inhibition in critical pathways: Unstable angina/non-st-segment elevation myocardial infarction. Clinical Cardiology, 1999, 22, 30-36.	1.8	27
260	Prehospital thrombolysis: An idea whose time has come. Clinical Cardiology, 1999, 22, 10-19.	1.8	27
261	Growth Differentiation Factor 15 at 1ÂMonth After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. Journal of the American Heart Association, 2017, 6, .	3.7	27
262	Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry. Diabetes Care, 2020, 43, 1843-1850.	8.6	27
263	Statin pretreatment and risk of in-hospital atrial fibrillation among patients undergoing cardiac surgery: a collaborative meta-analysis of 11 randomized controlled trials. Europace, 2015, 17, 855-863.	1.7	26
264	Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non–ST-Elevation Acute Coronary Syndrome. Clinical Chemistry, 2017, 63, 573-584.	3.2	26
265	Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the <scp>EXAMINE</scp> trial. Diabetes, Obesity and Metabolism, 2017, 19, 962-969.	4.4	26
266	Ertugliflozin and Slope of Chronic eGFR. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1345-1354.	4.5	26
267	Patient Characteristics Associated With the Choice of Triple Antithrombotic Therapy in Acute Coronary Syndromes. American Journal of Cardiology, 2009, 104, 1171-1178.	1.6	25
268	Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). American Journal of Cardiology, 2017, 120, 931-939.	1.6	25
269	The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Current Opinion in Lipidology, 2006, 17, 626-630.	2.7	24
270	Early Invasive Strategy Improves Outcomes in Patients With Acute Coronary Syndrome With Previous Coronary Artery Bypass Graft Surgery. Critical Pathways in Cardiology, 2006, 5, 167-172.	0.5	24

#	Article	IF	CITATIONS
271	Prognostic Evaluation of Catalytic Iron in Patients With Acute Coronary Syndromes. Clinical Cardiology, 2013, 36, 139-145.	1.8	24
272	Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the) Tj ETQq0 C 2015, 9, 65-71.) 0 rgBT /C 1.5	Overlock 10 Tf 24
273	Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function. Circulation, 2021, 143, 602-605.	1.6	24
274	Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f50-f60.	3.0	24
275	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal, 2016, 177, 1-8.	2.7	23
276	Medication Discontinuation in the IMPROVE-IT Trial. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005041.	2.2	23
277	Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 216-226.	3.0	23
278	Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2021, 77, 3016-3027.	2.8	23
279	LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials. Journal of Lipid Research, 2022, 63, 100148.	4.2	23
280	Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2022, 24, 1829-1839.	4.4	23
281	Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting. JAMA Cardiology, 2017, 2, 478.	6.1	22
282	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials. Circulation, 2021, 143, 685-695.	1.6	22
283	Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. Journal of the American College of Cardiology, 2021, 78, 1499-1507.	2.8	22
284	The role of cardiac Troponinâ€I (cTnl) in risk stratification of patients with unstable coronary artery disease. Clinical Cardiology, 1999, 22, 13-16.	1.8	21
285	Combination therapy for acute myocardial infarction: Glycoprotein ilb/iiia inhibitors plus thrombolysis. Clinical Cardiology, 1999, 22, 37-43.	1.8	21
286	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension, 2016, 68, 606-613.	2.7	21
287	Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. Diabetes Therapy, 2018, 9, 1317-1334.	2.5	21
288	Obesity-Related Cardiometabolic Complications. Clinical Cornerstone, 2008, 9, 11-22.	0.7	20

#	Article	IF	CITATIONS
289	Cardiovascular Disease and Modifiable Cardiometabolic Risk Factors. Clinical Cornerstone, 2008, 9, 24-41.	0.7	20
290	Relation Between Time of Symptom Onset of <scp>ST</scp> â€Segment Elevation Myocardial Infarction and Patient Baseline Characteristics: From the National Cardiovascular Data Registry. Clinical Cardiology, 2013, 36, 222-227.	1.8	20
291	Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome. European Journal of Preventive Cardiology, 2018, 25, 830-838.	1.8	20
292	Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the American College of Cardiology NCDR PINNACLE registry. American Heart Journal, 2018, 195, 50-59.	2.7	20
293	Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 3-11.	3.0	20
294	Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology, 2020, 75, 2119-2121.	2.8	20
295	Kidney outcomes using a sustained ≥40% decline in <scp>eGFR</scp> : A metaâ€analysis of <scp>SGLT2</scp> inhibitor trials. Clinical Cardiology, 2021, 44, 1139-1143.	1.8	20
296	Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 1072-1083.	4.4	20
297	High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome. Clinical Cornerstone, 2007, 8, S14-S23.	0.7	19
298	Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia. Coronary Artery Disease, 2017, 28, 190-197.	0.7	19
299	Average Clinicianâ€Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. Journal of the American Heart Association, 2018, 7, e009114.	3.7	19
300	Learning from the Recently Completed Oral Glycoprotein IIb/IIIa Receptor Antagonist Trials. Clinical Cardiology, 2000, 23, 14-17.	1.8	18
301	A Report of Quality Improvement in the Care of Patients With Acute Coronary Syndromes. Critical Pathways in Cardiology, 2011, 10, 29-34.	0.5	18
302	Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal, 2014, 168, 68-75.e2.	2.7	18
303	Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. Catheterization and Cardiovascular Interventions, 2017, 89, 190-198.	1.7	18
304	Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 2017, 44, 145-153.	2.1	18
305	Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. American Heart Journal, 2020, 219, 70-77.	2.7	18
306	The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. International Journal of Cardiology, 2020, 318, 126-129.	1.7	18

#	Article	IF	CITATIONS
307	Cardiovascular Ischemic Event Rates in Outpatients With Symptomatic Atherothrombosis or Risk Factors in the United States. Critical Pathways in Cardiology, 2009, 8, 91-97.	0.5	17
308	Non-ST-Elevation Myocardial Infarction Patients Who Present During Off Hours Have Higher Risk Profiles and are Treated Less Aggressively, but Their Outcomes are Not Worse. Critical Pathways in Cardiology, 2009, 8, 29-33.	0.5	17
309	Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. European Heart Journal: Acute Cardiovascular Care, 2017. 6. 500-510.	1.0	17
310	Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines–Coronary Artery Disease (GWTG-CAD) program. American Heart Journal, 2017, 187, 78-87.	2.7	17
311	Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. American Journal of Medicine, 2018, 131, 813-819.e5.	1.5	17
312	Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting. Clinical Cardiology, 2013, 36, 585-594.	1.8	16
313	Quality of Care for Patients With Acute Coronary Syndromes as a Function of Hospital Revascularization Capability: Insights From Get With The Guidelinesâ€ <scp>CAD</scp> . Clinical Cardiology, 2014, 37, 285-292.	1.8	16
314	Treatment of Hypertension in Patients with Coronary Artery Disease. A Case-Based Summary of the 2015 AHA/ACC/ASH Scientific Statement. American Journal of Medicine, 2016, 129, 372-378.	1.5	16
315	Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non–STâ€segment elevation acute coronary syndrome in the PLATO trial. Clinical Cardiology, 2017, 40, 390-398.	1.8	16
316	Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis, 2019, 288, 85-93.	0.8	16
317	Interleukinâ€18 in patients with acute coronary syndromes. Clinical Cardiology, 2019, 42, 1202-1209.	1.8	16
318	Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. ESC Heart Failure, 2021, 8, 1482-1493.	3.1	16
319	Time to treatment: A crucial factor in thrombolysis and primary angioplasty. Journal of Thrombosis and Thrombolysis, 1996, 3, 249-255.	2.1	15
320	On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). American Heart Journal, 2016, 182, 89-96.	2.7	15
321	Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLEâ€AF registry. Clinical Cardiology, 2019, 42, 339-345.	1.8	15
322	Switching warfarin to direct oral anticoagulants in atrial fibrillation: Insights from the NCDR PINNACLE registry. Clinical Cardiology, 2020, 43, 743-751.	1.8	15
323	Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008349.	3.9	15
324	Reducing Medication Errors Potential Benefits of Bolus Thrombolytic Agents. Academic Emergency Medicine, 2000, 7, 1285-1289.	1.8	14

#	Article	IF	CITATIONS
325	Acute Coronary Syndromes: Risk Stratification and Initial Management. Cardiology Clinics, 2005, 23, 401-409.	2.2	14
326	Circadian Variation in Patient Characteristics and Outcomes in ST-Segment Elevation Myocardial Infarction. Chronobiology International, 2012, 29, 1390-1396.	2.0	14
327	Serial Cardiac Troponin Measured Using a High-Sensitivity Assay inÂStable Patients With Ischemic Heart Disease. Journal of the American College of Cardiology, 2016, 68, 322-323.	2.8	14
328	Lower Onâ€Treatment Lowâ€Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. Journal of the American Heart Association, 2018, 7, e009221.	3.7	14
329	Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome. Clinical Research in Cardiology, 2021, 110, 1612-1624.	3.3	14
330	Evolving Management of ST-Segment Elevation Myocardial Infarction: Update on Recent Data. American Journal of Cardiology, 2006, 98, S10-S21.	1.6	13
331	Statins and safety: can we finally be reassured?. Lancet, The, 2011, 378, 1980-1981.	13.7	13
332	Circadian Variation of Stent Thrombosis and the Effect of More Robust Platelet Inhibition. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 555-559.	2.0	13
333	Evolving Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Results From a Survey Among <scp>US</scp> Cardiologists. Clinical Cardiology, 2014, 37, 103-107.	1.8	13
334	Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. American Heart Journal, 2016, 177, 33-41.	2.7	13
335	Relation Between Hospital Length of Stay and Quality of Care in Patients With Acute Coronary Syndromes (from the American Heart Association's Get With the Guidelines—Coronary Artery Disease) Tj ETQq1	1.0 .7843	1 £ BrgBT /O
336	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. New England Journal of Medicine, 2018, 378, 484-486.	27.0	13
337	Should real-world evidence be incorporated into regulatory approvals?. Expert Opinion on Drug Safety, 2018, 17, 1155-1159.	2.4	13
338	Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150Âmg doses. Journal of Clinical Lipidology, 2019, 13, 979-988.e10.	1.5	13
339	Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. American Heart Journal, 2019, 212, 13-22.	2.7	13
340	Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post–PCI in Patients WithÂAtrial Fibrillation and Diabetes. JACC: Cardiovascular Interventions, 2019, 12, 2346-2355.	2.9	13
341	Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatranâ€⁻+ Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarinâ€⁻+ Aspirinâ€⁻+ Clopidogrel or)	Ţj ETQq1	10.78431
342	Operative Management of Metastatic Melanoma in Bone May Require En Bloc Resection of Disease. Clinical Orthopaedics and Related Research, 2014, 472, 3196-3203.	1.5	12

#	Article	IF	CITATIONS
343	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). American Journal of Cardiology, 2019, 123, 382-391.	1.6	12
344	Efficacy and safety of alirocumab in statin-intolerant patients over 3Âyears: open-label treatment period of the ODYSSEY ALTERNATIVE trial. Journal of Clinical Lipidology, 2020, 14, 88-97.e2.	1.5	12
345	Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 153-163.	1.0	12
346	Oral platelet glycoprotein IIb/IIIa receptor inhibitors-part I. Clinical Cardiology, 2003, 26, 358-364.	1.8	11
347	Factors Associated With Discharge Lipid-Lowering Drug Prescription in Patients Hospitalized for Coronary Artery Disease (from the Get With the Guidelines Database). American Journal of Cardiology, 2008, 101, 1242-1246.	1.6	11
348	Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy. Journal of Thrombosis and Thrombolysis, 2013, 36, 233-239.	2.1	11
349	High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non–ST-segment elevation myocardial infarction. American Heart Journal, 2016, 171, 25-32.	2.7	11
350	Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. American Heart Journal, 2019, 216, 30-41.	2.7	11
351	Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease. American Journal of Cardiology, 2019, 123, 1202-1207	1.6	11
352	Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome. International Journal of Cardiology, 2014, 170, e59-e62.	1.7	10
353	Use of Renin–Angiotensin System Blockers in Acute Coronary Syndromes. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 227-235.	2.2	10
354	Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1927-1938.	4.4	10
355	Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. Sleep and Breathing, 2023, 27, 669-672.	1.7	10
356	Bridging the gap with new strategies in acute ST elevation myocardial infarction: bolus thrombolysis, glycoprotein IIb/IIIa inhibitors, combination therapy, percutaneous coronary intervention, and "facilitated" PCI. Journal of Thrombosis and Thrombolysis, 2000, 9, 235-241.	2.1	9
357	Targeted versus standard feedback: Results from a Randomized Quality Improvement Trial. American Heart Journal, 2015, 169, 132-141.e2.	2.7	9
358	Early and Chronic Dipeptidylâ€Peptidaseâ€₩ Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. Journal of the American Heart Association, 2018, 7, .	3.7	9
359	Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in AtrialÂFibrillation Patients After PCI. JACC: Cardiovascular Interventions, 2019, 12, 1553-1561.	2.9	9
360	What Do US Physicians and Patients Think About Lipid‣owering Therapy and Goals of Treatment? Results From the GOULD Registry. Journal of the American Heart Association, 2021, 10, e020893.	3.7	9

#	Article	IF	CITATIONS
361	Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 361-373.	4.5	9
362	Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE®). Critical Pathways in Cardiology, 2010, 9, 55-81.	0.5	8
363	Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e002951.	4.8	8
364	Predictors of Nonuse of a Highâ€Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladibâ€Thrombolysis in Myocardial Infarction 52 (SOLIDâ€TIMI 52) Trial. Journal of the American Heart Association, 2017, 6, .	3.7	8
365	Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	8
366	Selfâ€Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. Journal of the American Heart Association, 2017, 6, .	3.7	8
367	Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation. JACC: Cardiovascular Interventions, 2019, 12, 2331-2341.	2.9	8
368	Timeâ€Dependent Cardiovascular Treatment Benefit Model for Lipid‣owering Therapies. Journal of the American Heart Association, 2020, 9, e016506.	3.7	8
369	Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. European Journal of Preventive Cardiology, 2021, 28, e12-e14.	1.8	8
370	Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial. Drugs, 2020, 80, 995-1005.	10.9	8
371	Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill. JAMA Cardiology, 2020, 5, 532.	6.1	8
372	Impact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance Programs. Journal of the American Heart Association, 2020, 9, e014975.	3.7	8
373	Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program. American Heart Journal, 2022, 243, 15-27.	2.7	8
374	Advances in the medical management of acute coronary syndromes. , 1999, 7, 171-189.		7
375	Results of the Treat Angina With Aggrastat and Determine the Cost of Therapy With an Invasive or Conservative Strategy (TACTICS-TIMI 18) Trial: A Comparison of Invasive Versus Conservative Strategy in Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction. Circulation, 2000, 102, 2672-2672.	1.6	7
376	The endocannabinoid system:A new approach to control cardiovascular disease. Clinical Cornerstone, 2005, 7, 17-26.	0.7	7
377	Critical Pathways Using Platelet Testing to Potentially Optimize the Use of Oral Antiplatelet Therapy. American Journal of Cardiology, 2006, 98, S33-S38.	1.6	7
378	Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) Unstable Angina/Non-ST Elevation Myocardial Infarction Critical Pathway Toolkit. Critical Pathways in Cardiology, 2008, 7, 43-81.	0.5	7

#	Article	IF	CITATIONS
379	Individual Quality Improvement in Acute Coronary Syndromes. Critical Pathways in Cardiology, 2009, 8, 43-48.	0.5	7
380	Myocardial infarction vaccine? Evidence supporting the influenza vaccine for secondary prevention. European Heart Journal, 2011, 32, 1701-1703.	2.2	7
381	PCSK9 inhibitor valuation: A scienceâ€based review of the two recent models. Clinical Cardiology, 2018, 41, 544-550.	1.8	7
382	Ticagrelor in patients with heart failure after acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal, 2019, 213, 57-65.	2.7	7
383	Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry. Clinical Cardiology, 2020, 43, 1209-1215.	1.8	7
384	Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo. JACC: CardioOncology, 2020, 2, 385-396.	4.0	7
385	Risk markers of incident atrial fibrillation in patients with coronary heart disease. American Heart Journal, 2021, 233, 92-101.	2.7	7
386	Statin intolerance: how common is it and how do we work with patients to overcome it?. European Heart Journal, 2022, 43, 3224-3226.	2.2	7
387	Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial. American Journal of Nephrology, 2022, 53, 516-525.	3.1	7
388	The next step in cardiovascular protection. Atherosclerosis Supplements, 2003, 4, 3-9.	1.2	6
389	Treatment Algorithms and Critical Pathways for Acute Coronary Syndromes. Seminars in Vascular Medicine, 2003, 03, 425-432.	2.1	6
390	PROVE-IT TIMI 22 Study. Critical Pathways in Cardiology, 2003, 2, 188-196.	0.5	6
391	Clopidogrel: To Test or Not to Test? That Is the Question—Still. Clinical Chemistry, 2011, 57, 659-661.	3.2	6
392	Ticagrelor in Patients With Acute Coronary Syndromes and Stroke. Stroke, 2013, 44, 1477-1479.	2.0	6
393	Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines. American Heart Journal, 2016, 175, 1-8.	2.7	6
394	Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. American Heart Journal, 2016, 175-18-27	2.7	6
395	Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events. Current Cardiology Reports, 2018, 20, 55.	2.9	6
396	Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications. JAMA Cardiology, 2020, 5, 38.	6.1	6

#	Article	IF	CITATIONS
397	Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial. Journal of Clinical Lipidology, 2020, 14, 707-719.	1.5	6
398	Novel Oral Anticoagulants Following Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008465.	3.9	6
399	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1652-1659.	4.4	6
400	An overview of stroke and the impact of atrial fibrillation. American Journal of Managed Care, 2010, 16, S273-7.	1.1	6
401	Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. Clinical Cardiology, 2018, 41, 1022-1027.	1.8	5
402	The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT–TIMI 22. Clinical Cardiology, 2018, 41, 68-73.	1.8	5
403	No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. JACC: Cardiovascular Interventions, 2020, 13, 1012-1014.	2.9	5
404	Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006182.	2.2	5
405	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c <â€7% are associated with lower major cardiovascular events. American Heart Journal, 2020, 225, 97-107.	2.7	5
406	Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition. JAMA Cardiology, 2021, 6, 582.	6.1	5
407	Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCIÂTrial. JACC: Cardiovascular Interventions, 2021, 14, 768-780.	2.9	5
408	The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from <scp>VERTIS CV</scp> . Diabetes, Obesity and Metabolism, 2022, 24, 1114-1122.	4.4	5
409	Cardiorenal outcomes with ertugliflozin assessed according to baseline glucoseâ€lowering agent: An analysis from <scp>VERTIS CV</scp> . Diabetes, Obesity and Metabolism, 2022, , .	4.4	5
410	Impact of coronary artery calcium testing on patient management. Journal of Cardiovascular Computed Tomography, 2022, 16, 303-308.	1.3	5
411	A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial. EuroIntervention, 2022, 18, e292-e302.	3.2	5
412	Ischemic Preconditioning: Implications for the Geriatric Heart. The American Journal of Geriatric Cardiology, 2001, 10, 145-151.	0.6	4
413	Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) ST-Segment Elevation Myocardial Infarction Critical Pathway Toolkit. Critical Pathways in Cardiology, 2008, 7, 223-231.	0.5	4
414	Physician Practice Patterns in Acute Coronary Syndromes. Critical Pathways in Cardiology, 2010, 9, 23-29.	0.5	4

#	Article	IF	CITATIONS
415	Clinical Implications and Correlates of Q Waves in Patients With <scp>ST</scp> â€Elevation Myocardial Infarction Treated With Fibrinolysis: Observations from the <scp>CLARITYâ€TIMI</scp> 28 Trial. Clinical Cardiology, 2014, 37, 160-166.	1.8	4
416	No misrepresentation of vital status follow-up in PLATO: Predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial. International Journal of Cardiology, 2014, 176, 300-302.	1.7	4
417	Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management. Atherosclerosis, 2017, 263, 112-118.	0.8	4
418	Soluble interleukin-13rα1: a circulating regulator of glucose. American Journal of Physiology - Endocrinology and Metabolism, 2017, 313, E663-E671.	3.5	4
419	Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. Open Heart, 2017, 4, e000557.	2.3	4
420	Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet) Tj ETQq0 0 0	rgBT /Over 2.7	lock 10 Tf 5
421	Chronic kidney disease: a high-risk group that deserves intensive lipid lowering. European Heart Journal, 2020, 41, 4124-4126.	2.2	4
422	Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial. EuroIntervention, 2021, 17, 474-480.	3.2	4
	Cardiovascular Events and Longâ€Term Risk of Sudden Death Among Stabilized Patients After Acute		

423	Coronary Syndrome: Insights From IMPROVEâ€IT. Journal of the American Heart Association, 2022, 11, e022733.	3.7	4
424	Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial. Kidney International Reports, 2022, 7, 1782-1792.	0.8	4
425	Low levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: is there still a matter of debate?. European Heart Journal Open, 2022, 2, .	2.3	4
426	The Open Artery Hypothesis: Past, Present, and Future. Journal of Thrombosis and Thrombolysis, 1998, 5, 101-112.	2.1	3
427	Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis. Thrombosis Research, 2020, 195, 128-135.	1.7	3
428	ADP Receptor Antagonists. , 2008, , 87-123.		3
429	Textbook of Cardiovascular Medicine. Circulation, 1999, 100, 566-567.	1.6	3
430	Extending i2b2 into a framework for semantic abstraction of EHR to facilitate rapid development and portability of Health IT applications. AMIA Summits on Translational Science Proceedings, 2019, 2019, 370-378.	0.4	3
431	Utilization of Guidelines and Computer-Based Technology to Achieve Optimal Care in Atherothrombotic Vascular Disease, Journal of Thrombosis and Thrombolysis, 2004, 17, 45-49,	2.1	2

Introduction: Rationale for Tight Control of Hyperglycemia. American Journal of Cardiology, 2007, 99,
S1-S4.

#	Article	IF	CITATIONS
433	Should all surgery patients get statins pre-operatively? Clear or blurry VISION?. European Heart Journal, 2016, 37, 186-188.	2.2	2
434	Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease. Circulation, 2017, 136, 1860-1862.	1.6	2
435	Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status. American Journal of Cardiology, 2018, 122, 1451-1458.	1.6	2
436	Alteration of medical therapy in patients with heart failure relative to change in symptom severity. ESC Heart Failure, 2019, 6, 1085-1087.	3.1	2
437	Don't stop the statin!. European Heart Journal, 2019, 40, 3526-3528.	2.2	2
438	PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab. Journal of Clinical Lipidology, 2019, 13, 443-454.	1.5	2
439	Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2020, 75, 238-240.	2.8	2
440	EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL. Journal of the American College of Cardiology, 2020, 75, 215.	2.8	2
441	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. American Journal of Cardiology, 2020, 125, 1577-1581.	1.6	2
442	Role and Timing of Aspirin Therapy Following PCI in Patients With Atrial Fibrillation. American Journal of Cardiology, 2021, 144, S32-S39.	1.6	2
443	The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after <scp>PCI</scp> in patients with atrial fibrillation (a <scp>REâ€ĐUAL) Tj ETQq1 :</scp>	0.78431 1.8	4 rgBT /Over
444	Improving acute coronary syndrome care: the ACC/AHA guidelines and critical pathways. Journal of Invasive Cardiology, 2003, 15 Suppl B, 22B-27B; discussion 27B-29B.	0.4	2
445	New options for stroke prevention in atrial fibrillation. American Journal of Managed Care, 2010, 16, S291-7.	1.1	2
446	"Hot" unstable anginais it worse than subacute unstable angina? Results from the GUARANTEE Registry. Journal of Thrombosis and Thrombolysis, 2001, 12, 207-216.	2.1	1
447	Palm Pilot Programs to Improve Quality of Care in Acute Coronary Syndromes. Critical Pathways in Cardiology, 2002, 1, 113-115.	0.5	1
448	Complications of Acute Coronary Syndrome. , 2009, , 141-172.		1
449	Response to Letters Regarding Article, "Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial― Circulation, 2012, 125, .	1.6	1
450	Response to Letter Regarding Article, "Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATO― Circulation, 2012, 126, .	1.6	1

#	Article	IF	CITATIONS
451	Update on Pharmacological Cardiac Stress Testing: Efficacy, Risk Stratification and Patient Selection. American Journal of Medicine, 2014, 127, e16-e17.	1.5	1
452	Reply. Journal of the American College of Cardiology, 2016, 67, 3025-3026.	2.8	1
453	LOWER ON-TREATMENT LOW-DENSITY LIPOPROTEIN CHOLESTEROL IS ASSOCIATED WITH LOWER CARDIOVASCULAR RISK IN VERY HIGH RISK PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: ANALYSES FROM THE ODYSSEY TRIALS. Journal of the American College of Cardiology, 2017, 69, 55.	2.8	1
454	Reply. Journal of the American College of Cardiology, 2017, 70, 1200.	2.8	1
455	Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study. Thrombosis and Haemostasis, 2018, 118, 427-429.	3.4	1
456	Simulation Models of Therapy Intensification in Lipid-Lowering Medicine—Reply. JAMA Cardiology, 2018, 3, 89.	6.1	1
457	Reply to: Dual vs. triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. European Heart Journal, 2019, 40, 218-219.	2.2	1
458	TCT CONNECT-58 Evaluation of Antithrombotic Strategies Before and After the First Month of Therapy: Landmark Analysis of the RE-DUAL PCI Trial. Journal of the American College of Cardiology, 2020, 76, B24-B25.	2.8	1
459	Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. American Journal of Medicine, 2020, 133, 1302-1312.	1.5	1
460	Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. Journal of the American College of Cardiology, 2020, 75, 835-837.	2.8	1
461	Diagnosis of Acute Coronary Syndrome. , 0, , 13-35.		1
462	Abstract 16708: Increasing Age and the Benefit From Higher-intensity Lipid Lowering With Ezetimibe/Simvastatin vs. Simvastatin Alone: Results From the IMPROVE-IT Trial. Circulation, 2015, 132, .	1.6	1
463	Acute coronary syndrome. Cardiovascular events after clopidogrel discontinuation. Reviews in Cardiovascular Medicine, 2008, 9, 212-4.	1.4	1
464	Evaluating medical, percutaneous coronary intervention, and coronary artery bypass surgery options for chronic angina: an update of the revised guidelines. Reviews in Cardiovascular Medicine, 2009, 10 Suppl 1, S21-9.	1.4	1
465	Low molecular weight heparin in acute coronary syndromes. Current Cardiology Reports, 1999, 1, 206-211.	2.9	0
466	Post-Hospitalization Care of Patients with Acute Coronary Syndrome. , 2009, , 173-208.		0
467	Pathophysiology of Acute Coronary Syndromes. , 2009, , 1-12.		0
468	Unstable Angina and Non-ST-Elevation Myocardial Infarction. , 2009, , 37-78.		0

#	Article	IF	CITATIONS
469	Should We Measure Quality by the Dose?. Journal of the American College of Cardiology, 2013, 62, 1802-1803.	2.8	0
470	Response to Letter Regarding Article, "Ticagrelor in Patients With Acute Coronary Syndromes and Stroke: Interpretation of Subgroups in Clinical Trials". Stroke, 2013, 44, e95-e96.	2.0	0
471	Authors' Reply. Clinical Cardiology, 2014, 37, 323-323.	1.8	0
472	BIOMARKERS FOR PREDICTION OF OUTCOMES IN REVASCULARIZED PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME: A PLATO SUBSTUDY. Journal of the American College of Cardiology, 2014, 63, A45.	2.8	0
473	Authors' Reply. Clinical Cardiology, 2015, 38, 444-445.	1.8	0
474	Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT― Circulation, 2016, 133, e463.	1.6	0
475	Reply. Journal of the American College of Cardiology, 2016, 68, 981-982.	2.8	0
476	STREAM characterisation correction $\hat{a} \in \hat{a}$ Authors' reply. Lancet, The, 2017, 389, 2102-2103.	13.7	0
477	Addition or Removal of Guideline Directed Medical Therapy in Ambulatory Patients with Heart Failure with Reduced Ejection Fraction Relative to Change in Symptom Severity. An Analysis from the PINNACLE (Practice Innovation and Clinical Excellence) Registry. Journal of Cardiac Failure, 2017, 23, S51.	1.7	0
478	Anticoagulant Use in Heart Failure Patients with Atrial Fibrillation: Insights From the NCDR PINNACLE-AF Registry. Journal of Cardiac Failure, 2017, 23, S58.	1.7	0
479	Patients with Heart Failure with Mid-Range Ejection Fraction Have a Distinct Clinical Profile: An Analysis from the PINNACLE (Practice Innovation and Clinical Excellence) Registry. Journal of Cardiac Failure, 2017, 23, S51.	1.7	0
480	Long-term Safety and Efficacy of Lomitapide in Patients with Homozygous Familial Hypercholesterolemia: Three-Year Data from LOWER. Atherosclerosis Supplements, 2018, 32, 24.	1.2	0
481	Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved) Tj ETQq1 1	0.78 43 614 rgf	BT¢Overlock
482	Long-term Liver Safety of Lomitapide in Patients with Homozygous Familial Hypercholesterolemia: Three-year Data from LOWER. Atherosclerosis Supplements, 2018, 32, 153.	1.2	0
483	Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI. Journal of the American College of Cardiology, 2019, 74, 2431-2433.	2.8	0
484	Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older—Reply. JAMA Cardiology, 2020, 5, 235.	6.1	0
485	Reply. JACC: Cardiovascular Interventions, 2020, 13, 658-659.	2.9	0
486	SEX AND PERMANENT DRUG DISCONTINUATION IN CLINICAL TRIALS: INSIGHTS FROM THE TIMI TRIALS. Journal of the American College of Cardiology, 2020, 75, 3506.	2.8	0

#	Article	IF	CITATIONS
487	An Update on Aspirin for Cardioprevention: Implications for Patient Care. , 2021, 70, S1-S10.		0
488	Age and Routine Invasive Management of Acute Coronary Syndromes. Annals of Internal Medicine, 2004, 141, 967.	3.9	0
489	Empagliflozin (EMPA) Reduces Mortality and Hospitalization for Heart Failure (HHF) Irrespective of Cardiovascular (CV) Risk Score at Baseline. Diabetes, 2018, 67, 1123-P.	0.6	0
490	Composite Cardiovascular Risk Factor Target Achievement and Its Indicators in U.S. Adults with Diabetes—The Diabetes Collaborative Registry. Diabetes, 2018, 67, 1487-P.	0.6	0
491	8-OR: Use of Guideline-Recommended Risk-Reduction Strategies among Patients with Type 2 Diabetes and Established ASCVD: Insights from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD). Diabetes, 2019, 68, 8-OR.	0.6	0
492	The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events?. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e29-e30.	3.0	0
493	Clopidogrel: who, when, and how?. Reviews in Cardiovascular Medicine, 2007, 8 Suppl 3, S27-34.	1.4	0
494	How to develop a critical pathway: the acute coronary syndromes: Acute Cardiac Team to Implement Optimal Treatments Now (ACS ACTION) Program. Critical Pathways in Cardiology, 2002, 1, 53-60.	0.5	0
495	Percutaneous coronary intervention. Cardiovascular outcomes and long-term clopidogrel use after PCI in patients with diabetes. Reviews in Cardiovascular Medicine, 2008, 9, 280-2.	1.4	0
496	Introduction: Update on the evaluation and treatment of chronic angina. Reviews in Cardiovascular Medicine, 2009, 10 Suppl 1, S1-2.	1.4	0
497	Overview of clinical trials. Journal of Invasive Cardiology, 2004, 16 Suppl E, 7E-10E.	0.4	0
498	Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]. Diabetologia, 2022, 65, 908-911.	6.3	0
499	Review: Glycoprotein IIb/IIIa inhibitors reduce combined end points in acute coronary syndromes. ACP Journal Club, 2001, 134, 49.	0.1	0